Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,507,667
-
Total 13F shares
-
20,065,830
-
Share change
-
-15,031,137
-
Total reported value
-
$408,361,972
-
Put/Call ratio
-
44%
-
Price per share
-
$20.36
-
Number of holders
-
160
-
Value change
-
-$274,923,971
-
Number of buys
-
76
-
Number of sells
-
97
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q4 2025
As of 31 Dec 2025,
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) was held by
160 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,065,830 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP, STATE STREET CORP, Madison Avenue Partners, LP, ORBIMED ADVISORS LLC, Qube Research & Technologies Ltd, JACOBS LEVY EQUITY MANAGEMENT, INC, D. E. Shaw & Co., Inc., and FEDERATED HERMES, INC..
This page lists
160
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.